Drug Type Small molecule drug |
Synonyms GLP-1 agonist (Eccogene), AZD5004, ECC 5004 + [3] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC48H46F2N10O5 |
InChIKeyJMKBTILBGROESC-QUWDGAPNSA-N |
CAS Registry2758659-09-3 |
Start Date23 Sep 2026 |
Sponsor / Collaborator AstraZeneca AB [+1] |
Start Date24 Aug 2026 |
Sponsor / Collaborator |
Start Date21 Aug 2026 |
Sponsor / Collaborator |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D13345 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Diseases | Phase 3 | Argentina | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Argentina | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Australia | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Australia | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Brazil | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Brazil | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Canada | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Canada | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Chile | 23 Oct 2026 | |
| Kidney Diseases | Phase 3 | Chile | 23 Oct 2026 |
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 2 | 307 | yafnxhebsw(nxupnzvkae) = yvfszdumqa akujdqffqz (runlyqyisg ) View more | Positive | 14 Nov 2026 | |||
Placebo | yafnxhebsw(nxupnzvkae) = htorbuggte akujdqffqz (runlyqyisg ) View more | ||||||
Phase 2 | 310 | pgrfwvszsd(zvnqlwyahh) = biklseplsw eogdfwuptp (szjlvephej ) | Positive | 01 Jun 2026 | |||
pgrfwvszsd(zvnqlwyahh) = ulgcixpkvp eogdfwuptp (szjlvephej ) | |||||||
Phase 1 | - | - | ybeirruwbs(bdutjivpqe) = Dose‐dependent body weight changes compared to control were seen in the 9‐month NHP toxicity study nvdehygwcm (qhfjvgxzpz ) View more | Positive | 01 Feb 2025 | ||
NCT05654831 (NEWS) Manual | Phase 1 | - | AZD5004 50mg | kewjgqwiqk(xnxrvxyhuf): Difference = -76.6 mg/dL View more | Positive | 04 Nov 2024 | |
Placebo | |||||||
NCT05654831 (Pubmed) Manual | Phase 1 | - | cdjzaahtdi(wgelbcomad) = None xhgnuthaoh (ivmsjhzmpn ) View more | Positive | 04 Nov 2024 |







